Illumina, Inc.
NEWS
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
Illumina plans to continue to pursue its acquisition of Grail Inc. despite the objection of the U.S. Federal Trade Commission.
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a look at three of them.
Illumina, the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a life sciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
JOBS
IN THE PRESS